Physician profile
Humayun Shareef
NPI 1790843464
$2,741.18
in general payments reported to CMS, 2019-2025
34 companies · $232 in 2025
The $232 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $469 · 2020: $251 · 2021: $426 · 2022: $503 · 2023: $522 · 2024: $338 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,074 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.65 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $334.10 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Pfizer INC. | $200.09 | 2019-2025 | |
| Lilly USA, LLC | $198.37 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $187.98 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $178.15 | 2019-2024 | Airsupra |
| Exact Sciences Corporation | $164.17 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $149.06 | 2022-2023 | |
| Sunovion Pharmaceuticals INC. | $145.16 | 2020-2022 | |
| Dexcom, INC. | $134.83 | 2021-2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $110.34 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $102.41 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novo Nordisk INC | $97.15 | 2019-2023 | Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $89.95 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $88.36 | 2019-2023 | |
| Biogen, INC. | $71.64 | 2020-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.86 | 2021-2025 | Jardiance |
| Daiichi Sankyo INC. | $50.84 | 2023 | Injectafer |
| Abbott Laboratories | $33.46 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $32.07 | 2020-2023 | Eliquis |
| Vanda Pharmaceuticals INC. | $31.12 | 2020 | |
| Amarin Pharma, INC. | $30.16 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $26.22 | 2023 | Rexulti |
| Neurocrine Biosciences, INC. | $25.41 | 2023 | Ingrezza |
| Boston Scientific Corporation | $22.87 | 2023 | Watchman Flx |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.75 | 2022 | |
| Allergan, INC. | $20.83 | 2020 | |
| Abbvie INC. | $19.06 | 2021 | |
| Merck Sharp & Dohme LLC | $18.66 | 2022 | |
| Eisai INC. | $18.07 | 2021 | |
| Amgen INC. | $17.86 | 2023 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2019 | |
| Astellas Pharma US INC | $14.02 | 2021 | |
| Avanir Pharmaceuticals, INC. | $13.28 | 2021 | |
| Neurelis, INC. | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Humayun Shareef listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.